Skip to content
Back to search results

Cost-Utility Analysis

Introduced by
Health-economics community; standardised by Drummond and colleagues
Year
2015
Type
Economic evaluation expressing outcomes in utility-weighted health
Family
Economic appraisal
Font size

What does it do?

Cost-utility analysis (CUA) is a form of economic evaluation that compares the costs of alternative interventions with their outcomes expressed in a common, preference-based measure of health — most often the quality-adjusted life year (QALY), or in global health the disability-adjusted life year (DALY).

By combining length and quality of life into a single index, CUA allows interventions with very different effects to be compared on a like-for-like basis, and it produces an incremental cost-effectiveness ratio expressed as cost per QALY gained. It is the dominant method for informing decisions about which health technologies and programs to fund.

The intuition behind the method

How do you decide whether to fund a cancer drug that extends life or a hip replacement that improves mobility? Their benefits seem incomparable — months of survival versus years of less pain. Cost-utility analysis solves this by translating every health effect into one currency: the quality-adjusted life year. One QALY is a year of life in perfect health; a year lived at, say, 70 percent of full health counts as 0.7 QALYs. Now any intervention's benefit can be expressed as the QALYs it produces, and its value as the cost per QALY gained. A decision-maker with a fixed budget can then rank interventions and fund those that buy the most health per pound or dollar, up to a willingness-to-pay threshold. The QALY makes radically different treatments commensurable.

History

Cost-utility analysis grew out of health economics in the 1970s, when researchers including George Torrance developed methods to value health states and combine them with survival into the quality-adjusted life year. It became the centrepiece of health-technology assessment as agencies sought consistent ways to ration scarce health-care budgets. The UK's National Institute for Health and Care Excellence (NICE), established in 1999, embedded cost per QALY at the heart of its appraisals, and similar agencies worldwide followed. The methodology has been standardised and refined across editions of Drummond and colleagues' textbook Methods for the Economic Evaluation of Health Care Programmes, the field's authoritative reference.

When to use it

Use cost-utility analysis when comparing interventions whose benefits affect both length and quality of life, or whose effects are otherwise hard to compare, and when a decision-maker needs to allocate a fixed budget to maximise health gain — the standard situation in health-technology assessment and many public-health decisions. It assumes outcomes can be meaningfully captured by QALYs or DALYs and that preference-based utility values are available. It is less appropriate when benefits fall largely outside health (where cost-benefit analysis monetising all effects is better), when a single natural outcome unit suffices (cost-effectiveness analysis), or in contexts that reject the ethical premises of QALY weighting. It is a specialised member of the economic-evaluation family alongside cost-effectiveness and cost-benefit analysis.

Limitations and considerations

  • QALY weighting embeds contested ethical judgements, for example about valuing life-years across age and disability.
  • Utility values depend on the elicitation instrument and population, introducing measurement uncertainty.
  • Captures health benefits well but neglects effects outside health unless the perspective is broadened.
  • Cost-effectiveness thresholds are often poorly justified, yet decisions hinge on them.

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Makes interventions with very different effects comparable through the common QALY metric.
  • Captures both quality and length of life in a single, decision-relevant outcome.
  • Supports explicit, consistent priority-setting against a willingness-to-pay threshold.
  • Is the established reference-case method of major health-technology assessment agencies.

Applications

  • Health-technology assessment deciding whether to reimburse new drugs and devices.
  • Comparing public-health interventions such as screening and vaccination programs.
  • Informing clinical guidelines on the cost-effectiveness of treatment options.
  • Global-health priority-setting using DALYs to compare disease-control strategies.
  • Supporting resource-allocation decisions across competing health programs under a fixed budget.

How it works

How it works

1

The analyst defines the interventions being compared (including the relevant comparator or current practice), the patient population, the time horizon, and the analytic perspective — for example health-system or societal — which determines which costs and effects are counted. These framing choices, set out in reference cases by agencies such as NICE, shape every subsequent step and must be stated transparently.

2

All relevant costs over the time horizon are measured and valued, and future costs are discounted to present value at an agreed rate r, as in the formula where each period's cost c_t is divided by the compounding factor. Costs typically include the intervention itself plus downstream resource use such as hospitalisations, with the perspective dictating whether broader societal costs are included.

Formula
C = \sum_t \frac{c_t}{(1+r)^t}
3

Health outcomes are expressed as QALYs by weighting time spent in each health state by a utility value u_t between 0 (death) and 1 (full health), elicited from preference-based instruments such as the EQ-5D, and summing over the time horizon. This converts survival and quality-of-life effects into a single outcome measure comparable across very different conditions.

Formula
\text{QALY} = \sum_t u_t \cdot \Delta t
4

The incremental cost-effectiveness ratio (ICER) is computed as the difference in costs between two options divided by the difference in QALYs, giving the additional cost per additional QALY gained. The ICER is compared against a cost-effectiveness threshold representing the decision-maker's willingness to pay for a QALY; an intervention below the threshold is considered cost-effective.

Formula
\text{ICER} = \frac{C_A - C_B}{\text{QALY}_A - \text{QALY}_B}
5

Finally, uncertainty in the inputs is explored through sensitivity analysis — one-way, scenario and probabilistic — to test how robust the conclusion is to plausible variation in costs, utilities and clinical effectiveness. Probabilistic sensitivity analysis produces cost-effectiveness acceptability curves showing the probability that each option is cost-effective at different threshold values.

Common pitfalls

  • Comparing an intervention only to 'do nothing' while ignoring relevant current-practice comparators.
  • Mixing perspectives, so some costs are counted but related benefits are not.
  • Reporting an ICER as a point estimate without conveying the substantial uncertainty around it.
  • Treating a fixed threshold as a hard rule, ignoring its weak empirical basis and the budget impact.

Frequently asked questions

What is a QALY and how is it calculated?

A quality-adjusted life year combines length and quality of life into one number. Each year of life is weighted by a utility value between 0 (death) and 1 (full health) representing the quality of health during that year, and the weighted years are summed. For example, four years lived at a utility of 0.5 equal two QALYs. Utility values are usually derived from preference-based instruments such as the EQ-5D. The QALY lets interventions that affect survival, quality of life, or both be compared on a single scale.

How does cost-utility analysis differ from cost-effectiveness and cost-benefit analysis?

All three relate costs to outcomes. Cost-effectiveness analysis measures outcomes in a natural unit specific to the problem, such as cases detected or life-years gained, which limits comparison across different conditions. Cost-utility analysis uses the QALY (or DALY), a generic preference-based measure, so interventions for entirely different diseases can be compared. Cost-benefit analysis goes further and monetises all outcomes, allowing comparison beyond health but requiring a money value to be placed on health and life. CUA is essentially a specialised form of cost-effectiveness analysis using a utility-based outcome.

What is an ICER and how is it interpreted?

The incremental cost-effectiveness ratio is the extra cost of one intervention over its comparator divided by the extra QALYs it produces — the additional cost per additional QALY gained. It is judged against a cost-effectiveness threshold reflecting how much the decision-maker is willing to pay for a QALY: an ICER below the threshold suggests the intervention is good value. The ICER should always be reported with sensitivity analysis, because the underlying costs, utilities and effects are uncertain, and the threshold itself is a contested policy parameter rather than a scientific constant.

Related methods

Sources

  1. Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the Economic Evaluation of Health Care Programmes (4th ed.). Oxford: Oxford University Press.

    ISBN: 9780199665877
    Copied.